An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 28 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sodium benzoate (Primary)
Indications Schizophrenia
Focus Therapeutic Use
Sponsors SyneuRx International (Taiwan) corp

Most Recent Events

23 May 2024 Status changed from recruiting to discontinued.
10 Sep 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.
10 Sep 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight